丹麦制药企业诺和诺德将于2026年9月更名为诺和1。作为1923年成立的企业，该公司通过司美格鲁肽等创新药物在全球市场取得成功，其中司美格鲁肽至2025年已贡献公司总营收的近74%1。
诺和1994年进入中国，1995年在天津建厂，1997年在北京设立了跨国药企在华第一家研发中心1。与过往被动跟随的模式不同，该公司现已转变为主动参与，在化合物开发期就规划中国入组与注册路径1。近十年来，诺和研发投入占年销售收入10%以上1。
中国已成为诺和全球第二大单体市场，2026年上半年贡献营收97.44亿丹麦克朗（约合15.23亿美元），占全球的6.6%1。公司正将中国从单纯的创新目的地转变为创新启航地1。
这一战略调整恰逢中国代谢性疾病患者数量庞大的时期。中国成人糖尿病患者达1.48亿人，占全球糖尿病人口的四分之一；成人超重和肥胖患病率为56.9%，2.28亿成年人符合临床肥胖诊断标准1。
Novo Nordisk, the Danish pharmaceutical company founded in 1923, is rebranding and reorienting its research and development approach in China 1. The company will change its name to Novo effective September 2026 1, marking a symbolic transformation of its role in the world's second-largest economy.
The firm has fundamentally altered its China R&D model, transitioning from passive adaptation to proactive leadership 1. Rather than following market developments, Novo now integrates China into its compound development strategy from the outset, planning for Chinese patient enrollment and regulatory pathways during early research stages 1. This shift reflects China's growing importance: the country contributed 97.44 billion Danish kroner (approximately 15.23 billion US dollars) to Novo's revenue in the first half of 2026, representing 6.6 percent of global sales and establishing it as the company's second-largest single market 1.
Novo's expansion in China traces back decades 1. The company entered the Chinese market in 1994, established manufacturing operations in Tianjin in 1995, and opened its first research and development center in Beijing in 1997, pioneering the model of multinational pharmaceutical R&D facilities in China 1. The company invests over 10 percent of annual sales revenue into research and development 1, positioning itself to address significant market opportunities. China faces substantial health challenges: approximately 148 million adults have diabetes, accounting for one-quarter of the global diabetic population, while 228 million adults meet clinical obesity diagnostic criteria amid an overall adult overweight and obesity prevalence rate of 56.9 percent 1. Novo's semaglutide has emerged as a cornerstone product, contributing nearly 74 percent of total company revenue by 2025 1.
评论
还没有评论，欢迎留下第一条。